Evidence map›Paper›PMID 38165571›Full record

ArticleJournal of molecular histology2024

The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.

Fengrong Chen, Jiong Jiang, Dong Liu, Hong Li, Lei Dong, Yahua Song, Ying Zhang, Jing Wang, Yun Qin, Gang Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Fengrong Chen *Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Jiong Jiang *Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Dong LiuDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Hong LiDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Lei DongDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Yahua SongDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Ying ZhangDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Jing WangDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Yun QinDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China.
Gang ZhaoDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi Wu Road, Xi'an, 710003, Shaanxi, China. Gangzhao799@163.com.ORCID http://orcid.org/0000-0003-1482-1638
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

National Natural Science Foundation of China 81500423the Basic and Applied Research Promotion Engineering/Medical Research Project of Xi'an Science and Technology Plan 21YXYJ0118the Demonstration of standardized control and management of malignant tumor of digestive system in ansai county, northern shaanxi (The central government directs special funds for local science and technology development 2016ZY-HM-01the General Project in the Field of Social Development of Shaanxi Provincial Department of Science and Technology: the research on the mechanism and potential clinical significance of new long chain non coding RNA AC006262.5 in promoting hepatocellular car 2020SF-065the General Project of Key Research and Development Projects of Shaanxi Province: the experimental study of EGCG against liver fibrosis through mir-1207-5p 2021SF-224
6 · The paper itself

Abstract

Acquired drug resistance is a main reason for limiting the application of sorafenib in HCC treatment. This study aimed to explore the role and mechanisms of a novel long non-coding RNA (lncRNA), lnc-TSI, in sorafenib resistance of HCC. The interaction between lnc-TSI and miR-4726-5p, and miR-4726-5p and KCNMA1 were predicted using bioinformatic tools. Expression of the molecules in the lnc-TSI/miR-4726-5p/KCNMA1 axis in clinical samples and cell lines, as well as the sorafenib resistant HCC cell lines, was determined using qRT-PCR or western blotting. Expressions of lnc-TSI, miR-4726-5p, and KCNMA1 were manipulated in HepG2 and Huh7 cells through plasmid transfection or lentivirus infection. The CCK-8, flow cytometry, and Tunel assays were employed to determine the role of this axis on sorafenib resistance of HCC. A xenograft model was established using sorafenib-resistant HepG2 and Huh7 cells followed by in vivo sorafenib treatments to confirm the in vitro findings. Lnc-TSI and KCNMA1 expressions were significantly downregulated in HCC clinical samples and cell lines, especially in sorafenib resistance ones, while mi-4726-5p presented a reversed expression pattern. Lnc-TSI interacted with miR-4726-5p, and Lnc-TSI acts as a ceRNA via sponging miR-4726-5p in HCC cells. Overexpression of lnc-TSI and KCNMA1 promoted apoptosis and decreased cell viability of sorafenib-treated HCC cells, thus alleviated sorafenib resistance. miR-4726-5p mimic reversed the KCNMA1-mediated sorafenib sensitivity-promoting effect, while additional overexpression of lnc-TSI reversed the effect of miR-4726-5p. In vivo analysis also showed that overexpression of ln-TSI diminished sorafenib resistance in mice inoculated with sorafenib-resistant HCC cells via increasing KCNMA1 expression and decreasing miR-4726-5p expression. The lnc-TSI/miR-4726-5p/KCNMA1 axis plays a critical role in regulating the resistance of HCC to sorafenib, and might serve as a therapeutic target to manage sorafenib resistance of HCC in clinic.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsRNA, Long NoncodingAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansLarge-Conductance Calcium-Activated Potassium Channel alpha SubunitsMiceSorafenibKCNMA1 protein, humanLarge-Conductance Calcium-Activated Potassium Channel alpha SubunitsMicroRNAsRNA, Long NoncodingSorafenibceRNA mechanismHepatocellular carcinomaKCNMA1lnc-TSImiR-4726-5pSorafenib resistance

Identifiers

PMID38165571
OpenAlexW4390528195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.